CG Oncology Exceeds Even The 'Most Bullish Conversations;' Shares Break Out
This Biotech Stock Is Up 291% From Its IPO Price. It’s On Pace for a Record Closing High.
CG Oncology drug delivers ‘exceptional’ results in key bladder cancer trial
CG Oncology’s stock up as gene therapy gains second win in NMIBC
CG Oncology Reports 68% Reduction in Bladder Cancer Recurrence Risk in Phase 3 PIVOT-006 Trial
PIVOT-006 Phase 3 Registrational Trial Demonstrates Unprecedented Improvement in Recurrence-Free Survival (RFS) for Intermediate-Risk and High-Grade Ta Non-Muscle Invasive Bladder Cancer (NMIBC)
CG Oncology Announces Topline Results From Its Phase 3 PIVOT-006 Trial; Achieved Primary Endpoint With Compelling Safety And Tolerability Results
What CG Oncology (CGON)'s Third Quarter Earnings Means For Shareholders
Guggenheim Maintains Buy on CG Oncology, Lowers Price Target to $89
CG Oncology Reports Third Quarter 2026 Financial Results and Provides Business Updates
CG Oncology Q3 EPS $(0.64) Beats $(0.82) Estimate, Sales $1.604M Beat $643.584K Estimate
CG Oncology: A Second-Mover Advantage In Bladder-Sparing Therapy
How Investors May Respond To CG Oncology (CGON) Hiring a CCO Before Potential Bladder Cancer Launch
CG Oncology Appoints Proven Biopharmaceutical Commercial Leader Isabel Kalofonos as Chief Commercial Officer
CG Oncology, Inc. (CGON) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
CG Oncology (CGON) Stock Looks Fully Priced After A 160% Run
CG Oncology to Present at Upcoming Investor Conferences in September
CG Oncology (NASDAQ:CGON) Flaunts a Perfect Technical Breakout Setup
CG Oncology: Circling Back After Huge Rally
RBC Capital Maintains Outperform on CG Oncology, Lowers Price Target to $79
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.